.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AX07_DimethylFumarate.DimethylFumarate .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AX07_DimethylFumarate.DimethylFumarate| name: | DimethylFumarate | |
| ATC code: | L04AX07 | route: | oral |
| compartments: | 1 | |
| dosage: | 240 | mg |
| volume of distribution: | 53 | L |
| clearance: | 96 | L/h |
| other parameters in model implementation | ||
Dimethyl fumarate is an oral immunomodulatory drug approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and also used in the management of moderate to severe plaque psoriasis. It acts by activating the Nrf2 pathway and reducing oxidative stress and inflammation.
Pharmacokinetic parameters are reported for healthy adult volunteers and patients with relapsing-remitting multiple sclerosis (RRMS), following oral administration.
Hosseini, A, et al., & Jadidi-Niaragh, F (2019). Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis. Journal of cellular physiology 234(7) 9943–9955. DOI:10.1002/jcp.27930 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30536402